Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gaboxadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gaboxadol SCHEMBL247815 | 0.98 | CHRM3 (0.46) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL5533785 | 0.98 | CHRM3 (0.46) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983708 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403323 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3981267 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL23851948 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3979055 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3980688 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983776 | 0.96 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL567225 | 0.96 | CHRM3 (0.49) | CHRM3HTR2CCHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085913-A1 | Polymorphic Forms of a Gabaa Agonist | H. LUNDBECK A/S (DK) | 2008-04-10 | — | — | US | claimed |
| EP-1848420-A4 | POLYMORPHIC FORMS OF A GABAA AGONIST | MERCK & CO INC (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1848420-A2 | POLYMORPHIC FORMS OF A GABAA AGONIST | Merck & Co., Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006083682-A2 | POLYMORPHIC FORMS OF A GABAA AGONIST | H.LUNDBECK A/S (DK) | 2006-08-10 | — | — | WO | claimed |
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | US | disclosed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-11 | — | — | US | disclosed |
| US-8236958-B2 | Polymorphic forms of a GABAA agonist | H. LUNDBECK A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-8193216-B2 | Polymorphic forms of a GABAA agonist | H. LUNDBECK A/S (DK) | 2012-06-05 | — | — | US | disclosed |
| US-20110301190-A1 | POLYMORPHIC FORMS OF A GABAA AGONIST | H. LUNDBECK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20050171142-A1 | Polymorphic forms of a GABAA agonist | H. LUNDBECK A/S (DK) | 2005-08-04 | — | — | US | disclosed |
| WO-2005023820-A1 | METHOD FOR THE MANUFACTURE OF THIP | H. LUNDBECK A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| EP-0000338-B1 | ISOXAZOLO(5,4-C)PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | H.Lundbeck & Co., A/S (DK) | 1981-11-25 | — | — | EP | disclosed |
| US-4301287-A | FOR TREATMENT OF PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | H. LUNDBECK & CO. A/S (DK) | 1981-11-17 | — | — | US | disclosed |
| US-4278676-A | NERVOUS SYSTEM DISORDERS, CYCLIZATION, HYDROLYSIS | H. LUNDBECK & CO. A/S (DK) | 1981-07-14 | — | — | US | disclosed |
| EP-0028017-A1 | 3-Piperidinone-4-carboxylic acid derivatives | H.Lundbeck & Co., A/S (DK) | 1981-05-06 | — | — | EP | disclosed |
| EP-0027279-A1 | Isoxazolo(5,4-C)pyridines | H.Lundbeck & Co., A/S (DK) | 1981-04-22 | — | — | EP | disclosed |
| EP-0000338-A2 | Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them | H.Lundbeck & Co., A/S (DK) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | CHRM3 2466/4885HTR2C 2422/4885CHRM5 2426/4885 |
| US-20080085913-A1 | Polymorphic Forms of a Gabaa Agonist | GABRA5, GABRA4, GABRA3 | CHRM3 285/4885HTR2C 145/4885CHRM5 358/4885 |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | CHRM3 2466/4885HTR2C 2422/4885CHRM5 2426/4885 |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | MECP2, GABBR1, GABBR2 | CHRM3 2466/4885HTR2C 2422/4885CHRM5 2426/4885 |
| US-20200179374-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | CHRM3 2466/4885HTR2C 2422/4885CHRM5 2426/4885 |
| US-20050171142-A1 | Polymorphic forms of a GABAA agonist | GABRB3, GABRA3, GABRG3 | CHRM3 187/4885HTR2C 644/4885CHRM5 821/4885 |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | CHRM3 2466/4885HTR2C 2422/4885CHRM5 2426/4885 |
| US-20110301190-A1 | POLYMORPHIC FORMS OF A GABAA AGONIST | GABRA5, GABRA4, GABRA3 | CHRM3 285/4885HTR2C 145/4885CHRM5 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.